medi-570
mAbexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2010 (NCT01127321)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Inducible T-cell costimulatorINHIBITOR
ICOS inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109449 ↗
Also known as
- medi-570
- medi-570
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02520791 | Phase 1 | Apr 22, 2016 | National Cancer Institute (NCI), University of Toronto |
| NCT01127321 | Phase 1 | May 1, 2010 | AstraZeneca, MedImmune |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 1 | 0 | 1 | 2010 |
| MedImmune | For profit | 1 | 1 | 1 | 2010 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2016 |
| University of Toronto | Academic/Hospital | 1 | 0 | 1 | 2016 |
4 organizations
Page 1 / 1